INTECH Investment Management’s Denali Therapeutics DNLI Stock Holding History

INTECH Investment Management’s Portfolio DNLI Stock Details DNLI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$913K	Sell	35,484 -3,447	-9%	-$70.8K	0.01%	1078
2026 Q1	$747K	Sell	38,931 -13,701	-26%	-$273K	0.01%	1143
2025 Q4	$869K	Buy	52,632 +5,835	+12%	+$98.5K	0.01%	1205
2025 Q3	$679K	Sell	46,797 -25,069	-35%	-$360K	0.01%	1403
2025 Q2	$1.01M	Sell	71,866 -5,724	-7%	-$80.6K	0.01%	1190
2025 Q1	$1.05M	Buy	77,590 +30,189	+64%	+$578K	0.01%	1163
2024 Q4	$966K	Buy	47,401 +17,858	+60%	+$457K	0.01%	1173
2024 Q3	$861K	Buy	+29,543	New	+$732K	0.01%	900

Other funds holding DNLI

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

INTECH Investment Management's DNLI Position: Q2 2026 in Review

INTECH Investment Management reduced its Denali Therapeutics (DNLI) stake by 8.9% in Q2 2026, selling an estimated $70.8K and leaving 35,484 shares worth $913K. The position accounts for 0.01% of the portfolio, ranked #1078.

INTECH Investment Management first reported a position in DNLI in Q3 2024 and has held it in 8 quarters since. The position peaked at $1.05M in Q1 2025. 292 funds tracked by Wall St. Rank hold DNLI as of Q2 2026.

INTECH Investment Management held 35,484 shares of Denali Therapeutics worth $913K as of Q2 2026.
INTECH Investment Management sold 3,447 Denali Therapeutics shares in Q2 2026, an estimated $70.8K.
Denali Therapeutics made up 0.01% of INTECH Investment Management's portfolio in Q2 2026, its #1078 holding.
INTECH Investment Management first reported a position in Denali Therapeutics in Q3 2024 and has held it in 8 quarters since.
INTECH Investment Management's Denali Therapeutics position peaked at $1.05M in Q1 2025.
292 funds tracked by Wall St. Rank held Denali Therapeutics as of Q2 2026.

Based on INTECH Investment Management's 13F filing for Q2 2026, filed 10 Aug 2026.